Imipenem/Cilastatin

Imipenem and Cilastatin, the active ingredients in Imipenem/Cilastatin, are a carbapenem antibiotic combined with a renal dehydropeptidase inhibitor presented as an intravenous formulation for hospital use. It treats a broad range of serious bacterial infections in adult and pediatric patients.

GNH USA supplies Imipenem/Cilastatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/Cilastatin is employed for severe bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides effective bacterial clearance in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: eradicates resistant uropathogens in complicated cases. - Skin and soft‑tissue infections: treats deep or extensive infections caused by susceptible organisms. - Community‑acquired and hospital‑acquired pneumonia: covers a wide spectrum of respiratory pathogens. - Severe sepsis and septic shock: delivers rapid bactericidal activity in critically ill patients.

Adverse reactions may occur with any intravenous antibiotic and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limited. - Rash: skin erythema or mild pruritus.

Serious or Rare Side Effects: - Seizures: especially in patients with pre‑existing CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated colitis that can be life‑threatening.

Use of Imipenem/Cilastatin requires careful clinical assessment.

- Renal function: adjust dosing in patients with impaired clearance. - Seizure risk: monitor individuals with a history of seizures or CNS disease. - Allergy: avoid in patients with known hypersensitivity to carbapenems. - Drug interactions: review concomitant medications that may lower seizure threshold. - Pregnancy and lactation: prescribe only when the potential benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Imipenem/Cilastatin can interact with several drug classes.

Major Interactions (Avoid): - Valproic acid: may increase risk of seizures. - Other carbapenems: concurrent use can lead to additive toxicity. - Probenecid: may raise plasma concentrations of imipenem. - CNS stimulants: can lower seizure threshold.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolyte balance. - Anticoagulants: watch for altered INR values. - Oral contraceptives: may reduce hormonal efficacy.